Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers

Rundquist, Sara; Sachs, Michael; Eriksson, Carl; Olén, Ola; Montgomery, Scott; Halfvarson, Jonas

doi:10.1111/apt.16193

Cited by 22 publications

(6 citation statements)

References 45 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies using DS as an efficacy endpoint are fewer in number. A nationwide Swedish register-based study assessing DS for second-line treatment with IFX and VDZ showed similar DS between these medications [ 13 ]. Based on a claims database, a second study from the USA described drug persistence (sustainability) tendencies, with slightly longer drug persistence for IFX, without direct comparison between the drugs and no adjustment to different factors that might affect DS [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data

Konikoff,

Yanai,

Libchik

et al. 2023

JCM

View full text Add to dashboard Cite

Background and Aim: Drug sustainability (DS) is a surrogate marker for treatment efficacy. We aimed to compare the DS of two main biologics used to treat moderate-to-severe ulcerative colitis (UC), infliximab (IFX) and vedolizumab (VDZ), in a real-world setting. Methods: We conducted a retrospective cohort study at a tertiary medical center in Israel. We included patients treated between 1 December 2017 and 1 May 2021, who were followed for up to 300 weeks. DS was defined as corticosteroid-, surgical-, and hospitalization-free treatment. Results: 217 patients with UC were included. VDZ had a significantly longer median DS of 265.6 weeks compared to IFX’s 106.5 weeks (p = 0.001) in treatment-naïve patients, even when adjusting for disease severity (HR 0.55 95 CI 0.3–0.98, p = 0.042). In treatment-experienced patients, DS was comparable between IFX and VDZ (p = 0.593). Conclusions: VDZ showed significantly longer DS in treatment-naïve patients with UC compared to IFX, also when adjusted for disease severity. There was no difference in DS between VDZ and IFX in treatment-experienced patients and patients switching from one drug to another. VDZ may be a suitable first-line treatment for biologic-naïve patients with moderate-to-severe UC.

show abstract

Section: Discussionmentioning

confidence: 99%

Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data

Konikoff,

Yanai,

Libchik

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…TNF inhibitors are Infliximab, Adalimumab, Golimumab and Certolizumab pegol. They antagonize TNF receptors and induce inhibition of immune responses by TNF, thus inducing recovery and maintenance of remission of CD and UC [ 55 ]. Generally, the most common manifestation of anti-TNF hepatotoxicity is acute hepatocellular damage, which occurs on average 13 weeks after the start of therapy.…”

Section: Biologic Therapiesmentioning

confidence: 99%

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Catanzaro,

Marotta,

Yazdani

et al. 2024

Toxics

View full text Add to dashboard Cite

Drug-induced liver disease (DILI) represents one of the main problems in the therapeutic field. There are several non-modifiable risk factors, such as age and sex, and all drugs can cause hepatotoxicity of varying degrees, including those for the treatment of inflammatory bowel diseases (IBD). The aim of this review is to illustrate the adverse effects on the liver of the various drugs used in the treatment of IBD, highlighting which drugs are safest to use based on current knowledge. The mechanism by which drugs cause hepatotoxicity is not fully understood. A possible cause is represented by the formation of toxic metabolites, which in some patients may be increased due to alterations in the enzymatic apparatus involved in drug metabolism. Various studies have shown that the drugs that can most frequently cause hepatotoxicity are immunosuppressants, while mesalazine and biological drugs are, for the most part, less associated with such complications. Therefore, it is possible to assume that in the future, biological therapies could become the first line for the treatment of IBD.

show abstract

“…As the first biological agents, anti-tumor necrosis factor (anti-TNF) monoclonal antibodies, mainly including infliximab and adalimumab, have been widely used to treat moderate to severe IBD patients over the past two decades and have been proven effective and mature ( Derkx et al, 1993 ; D'Haens and van Deventer, 2021 ; Rundquist et al, 2021 ). Unfortunately, 10%–40% of patients fail to respond favorably to the anti-TNF therapies for the first time, which is called primary non-response (PNR) ( Ben-Horin et al, 2014 ; Papamichael et al, 2015 ; Sabino et al, 2019 ; Marsal et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Antibiotics influence the risk of anti-drug antibody formation during anti-TNF therapy in Chinese inflammatory bowel disease patients

Sun,

Ju,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Aims: The formation of anti-drug antibodies (ADAs) during anti-tumor necrosis factor (anti-TNF) therapy is reported to lead to reducing serum drug levels, which may bring about a loss of response to treatment. Previous research has suggested an association between specific antibiotic classes and ADA formation during anti-TNF therapy. However, there are few studies specifically examining this association in Chinese inflammatory bowel disease (IBD) patients. Therefore, our study aimed to evaluate the possible effect of antibiotic use on ADA formation to anti-TNF therapy in Chinese patients with IBD.Methods: A total of 166 patients with IBD, including 149 with Crohn’s disease (CD) and 17 with ulcerative colitis (UC), were included in this retrospective analysis. These patients were initially treated with anti-TNF therapy (infliximab or adalimumab) after January 2018 and reviewed with available ADA levels before October 2023. After univariable analysis of all the variables, a multivariate Cox proportional hazards model was used to assess the association between antibiotic use and ADA development.Results: Among 166 IBD patients treated with infliximab (108/166, 65.1%) or adalimumab (58/166, 34.9%), 31 patients (18.7%) were measured as positive ADA levels. Cox proportional hazard model demonstrated an increased risk of ADA formation in IBD patients who used β-lactam-β-lactamase inhibitor combinations (BL-BLIs) (HR = 5.143, 95%CI 1.136–23.270, p = 0.033), or nitroimidazoles (HR = 4.635, 95%CI 1.641–13.089, p = 0.004) during 12 months before the ADA test. On the contrary, a reduced risk was noted in patients treated with fluoroquinolones (HR = 0.258, 95% CI 0.072–0.924, p = 0.037). Moreover, the median serum infliximab or adalimumab concentration in patients with positive ADA levels was significantly lower than that in patients with negative ADA levels (infliximab: 0.30 vs. 1.85 μg/mL, p < 0.0001; adalimumab: 0.45 vs. 7.55 μg/mL, p = 0.0121).Conclusion: ADA development is associated with various antibiotic classes. BL-BLIs and nitroimidazoles might increase the risk of ADA formation during anti-TNF therapy in Chinese IBD patients, while the treatment with fluoroquinolones could probably reduce such risk. There were certain limitations in the retrospective analysis of the study, therefore, the results are just for reference, and other studies are needed to further confirm our findings.

show abstract

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers

Cited by 22 publications

References 45 publications

Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data

Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Antibiotics influence the risk of anti-drug antibody formation during anti-TNF therapy in Chinese inflammatory bowel disease patients

Contact Info

Product

Resources

About